The mTOR inhibitor, CCI-779, is effective against myeloma growth in vivo.

被引：0
|
作者：
Frost, P [1 ]
Gera, J [1 ]
Shi, YJ [1 ]
Lichtenstein, A [1 ]
机构：
[1] Univ Calif Los Angeles, W LA VA Med Ctr, Los Angeles, CA USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1626
引用
收藏
页码：445A / 445A
页数：1
相关论文
共 50 条
  • [41] Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
    Wu, LC
    Birle, DC
    Tannock, IF
    [J]. CANCER RESEARCH, 2005, 65 (07) : 2825 - 2831
  • [42] The mTOR inhibitor radon (everolimus) inhibits myeloma tumor growth in vivo
    Campbell, R.
    Sanchez, E.
    Steinberg, J.
    Chen, H.
    Shalitin, D.
    Li, M.
    Wang, C.
    Pang, S.
    Bonavida, B.
    Said, J.
    Berenson, J.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 149 - 149
  • [43] The mTOR inhibitor temsirolimus (CCI-779) induces cell cycle arrest and autophagy in Hodgkin lymphoma (HL) cell lines and enhances the effect of the p13-kinase inhibitor LY294002.
    Georgakis, Georgios V.
    Yazbeck, Victor Y.
    Li, Yang
    Younes, Anas
    [J]. BLOOD, 2006, 108 (11) : 639A - 639A
  • [44] Molecular inhibition of mTOR with temsirolimus (TORISEL™, CCI-779) is a promising strategy in relapsed NHL:: The University of Chicago phase II consortium.
    Smith, Sonali M.
    Pro, Barbara
    Smith, Scott
    Stiff, Patrick
    Lester, Eric
    Modi, Sanjiv
    van Besien, Koen
    [J]. BLOOD, 2006, 108 (11) : 703A - 704A
  • [45] GEMCITABINE COMBINED WITH THE MTOR INHIBITOR TEMSIROLIMUS(CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER (HE 3/07). A PHASE I STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
    Karavasilis, V.
    Pentheroudakis, G.
    Sgouros, J.
    Dimoudis, S. T.
    Varthalitis, I.
    Samantas, E.
    Fountzilas, G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 239 - 239
  • [46] Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
    Ekshyyan, Oleksandr
    Rong, Youhua
    Rong, Xiaohua
    Pattani, Kavita M.
    Abreo, Fleurette
    Caldito, Gloria
    Chang, John Kai Siung
    Arnpil, Federico
    Glass, Jonathan
    Nathan, Cherie-Ann O.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (08) : 2255 - 2265
  • [47] Combination of a rapamycin analog (CCI-779) and interferon-γ is more effective than single agents in treating a mouse model of tuberous sclerosis complex
    Lee, Laifong
    Sudentas, Paul
    Dabora, Sandra L.
    [J]. GENES CHROMOSOMES & CANCER, 2006, 45 (10): : 933 - 944
  • [48] A new Pharmacologic action of CCI-779 involves FKBP12-Independent inhibition of mTOR kinase activity and profound repression of global protein synthesis
    Shor, Boris
    Zhang, Wei-Guo
    Toral-Barza, Lourdes
    Lucas, Jessica
    Abraham, Robert T.
    Gibbons, James J.
    Yu, Ker
    [J]. CANCER RESEARCH, 2008, 68 (08) : 2934 - 2943
  • [49] Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth
    Gallicchio, MA
    van Sinderen, M
    Bach, LA
    [J]. HORMONE AND METABOLIC RESEARCH, 2003, 35 (11-12) : 822 - 827
  • [50] Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737
    Ricciardi, Maria Rosaria
    Decandia, Samantha
    Bergamo, Paola
    De Benedictis, Cinzia
    Vitale, Antonella
    Testi, Anna Maria
    Fei, Joanna
    Petrucci, Maria Teresa
    Milella, Michele
    Foa, Robin
    Tafuri, Agostino
    [J]. BLOOD, 2009, 114 (22) : 409 - 409
12345